{"id":"W2087700674","doi":"10.1111/bjh.12274","title":"The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase <scp>III</scp> study in patients with myelofibrosis","year":2013,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Incyte","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Placebo; Internal medicine; Randomization; International Prognostic Scoring System; Population; Polycythaemia; Gastroenterology; Clinical trial; Surgery; Myelodysplastic syndromes; Bone marrow; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006820914,0.001550829,0.003897628,0.0004352161,0.0004230863,0.001374209,0.0007866443,0.001635684,0.002457364],"category_scores_gemma":[0.004381738,0.0006401669,0.003875882,0.0005412411,0.001304023,0.0009784218,0.0004514167,0.002589559,0.0004066972],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008694312,"about_ca_system_score_gemma":0.001085957,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005906975,"about_ca_topic_score_gemma":0.001358406,"domain_scores_codex":[0.9966329,0.002323233,0.0002467002,0.0003796313,0.0001968151,0.0002207292],"domain_scores_gemma":[0.9964413,0.001284071,0.0009863762,0.0004657305,0.0002185342,0.0006039331],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9749749,0.003503094,0.001177189,0.0003837908,0.00248199,0.00002771846,0.00004431963,0.0003744163,0.005862837,0.000046129,0.0003311443,0.01079247],"study_design_scores_gemma":[0.8276976,0.1592657,0.00825216,0.00003599572,0.002405086,0.00005230572,0.00002850229,0.0005254118,0.0009907313,0.0001151231,0.0006005558,0.0000309339],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912506,0.00435701,0.00058749,0.0003146623,0.000206137,0.001694498,0.0008344845,0.00006643723,0.0006886189],"genre_scores_gemma":[0.9933755,0.001490624,0.0009535729,0.000438949,0.0002999571,0.001770337,0.001033767,0.0000226276,0.0006146662],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006820914,"threshold_uncertainty_score":0.03607291,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01525759521435154,"score_gpt":0.3194535140610985,"score_spread":0.3041959188467469,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}